A novel, stable, aqueous Glucagon formulation using Ferulic acid as an Excipient

Parkash A. Bakhtiani, Nicholas Caputo, Jessica Castle, Joseph El Youssef, Julie M. Carroll, Larry David, Charles Roberts, Ward Kenneth

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Commercial glucagon is unstable due to aggregation and degradation. In closed-loop studies, it must be reconstituted frequently. For use in a portable pump for 3 days, a more stable preparation is required. At alkaline pH, curcumin inhibited glucagon aggregation. However, curcumin is not sufficiently stable for long-Term use. Here, we evaluated ferulic acid, a stable breakdown product of curcumin, for its ability to stabilize glucagon. Methods: Ferulic acid-formulated glucagon (FAFG), composed of ferulic acid, glucagon, L-methionine, polysorbate-80, and human serum albumin in glycine buffer at pH 9, was aged for 7 days at 37°C. Glucagon aggregation was assessed by transmission electron microscopy (TEM) and degradation by high-performance liquid chromatography (HPLC). A cell-based protein kinase A (PKA) assay was used to assess in vitro bioactivity. Pharmacodynamics (PD) of unaged FAFG, 7-day aged FAFG, and unaged synthetic glucagon was determined in octreotide-Treated swine. Results: No fibrils were observed in TEM images of fresh or aged FAFG. Aged FAFG was 94% intact based on HPLC analysis and there was no loss of bioactivity. In the PD swine analysis, the rise over baseline of glucose with unaged FAFG, aged FAFG, and synthetic native glucagon (unmodified human sequence) was similar. Conclusions: After 7 days of aging at 37°C, an alkaline ferulic acid formulation of glucagon exhibited significantly less aggregation and degradation than that seen with native glucagon and was bioactive in vitro and in vivo. Thus, this formulation may be stable for 3-7 days in a portable pump for bihormonal closed-loop treatment of T1D.

Original languageEnglish (US)
Pages (from-to)17-23
Number of pages7
JournalJournal of diabetes science and technology
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

ferulic acid
Excipients
Glucagon
Acids
Agglomeration
Pharmacodynamics
Curcumin
High performance liquid chromatography
Bioactivity
Degradation
Pumps
Transmission electron microscopy
Transmission Electron Microscopy

Keywords

  • closed-loop system
  • ferulic acid
  • glucagon
  • hypoglycemia
  • type 1 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

A novel, stable, aqueous Glucagon formulation using Ferulic acid as an Excipient. / Bakhtiani, Parkash A.; Caputo, Nicholas; Castle, Jessica; El Youssef, Joseph; Carroll, Julie M.; David, Larry; Roberts, Charles; Kenneth, Ward.

In: Journal of diabetes science and technology, Vol. 9, No. 1, 01.01.2015, p. 17-23.

Research output: Contribution to journalArticle

@article{a8b0921387f04cf49ba4947316f9116b,
title = "A novel, stable, aqueous Glucagon formulation using Ferulic acid as an Excipient",
abstract = "Background: Commercial glucagon is unstable due to aggregation and degradation. In closed-loop studies, it must be reconstituted frequently. For use in a portable pump for 3 days, a more stable preparation is required. At alkaline pH, curcumin inhibited glucagon aggregation. However, curcumin is not sufficiently stable for long-Term use. Here, we evaluated ferulic acid, a stable breakdown product of curcumin, for its ability to stabilize glucagon. Methods: Ferulic acid-formulated glucagon (FAFG), composed of ferulic acid, glucagon, L-methionine, polysorbate-80, and human serum albumin in glycine buffer at pH 9, was aged for 7 days at 37°C. Glucagon aggregation was assessed by transmission electron microscopy (TEM) and degradation by high-performance liquid chromatography (HPLC). A cell-based protein kinase A (PKA) assay was used to assess in vitro bioactivity. Pharmacodynamics (PD) of unaged FAFG, 7-day aged FAFG, and unaged synthetic glucagon was determined in octreotide-Treated swine. Results: No fibrils were observed in TEM images of fresh or aged FAFG. Aged FAFG was 94{\%} intact based on HPLC analysis and there was no loss of bioactivity. In the PD swine analysis, the rise over baseline of glucose with unaged FAFG, aged FAFG, and synthetic native glucagon (unmodified human sequence) was similar. Conclusions: After 7 days of aging at 37°C, an alkaline ferulic acid formulation of glucagon exhibited significantly less aggregation and degradation than that seen with native glucagon and was bioactive in vitro and in vivo. Thus, this formulation may be stable for 3-7 days in a portable pump for bihormonal closed-loop treatment of T1D.",
keywords = "closed-loop system, ferulic acid, glucagon, hypoglycemia, type 1 diabetes mellitus",
author = "Bakhtiani, {Parkash A.} and Nicholas Caputo and Jessica Castle and {El Youssef}, Joseph and Carroll, {Julie M.} and Larry David and Charles Roberts and Ward Kenneth",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/1932296814552476",
language = "English (US)",
volume = "9",
pages = "17--23",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "1",

}

TY - JOUR

T1 - A novel, stable, aqueous Glucagon formulation using Ferulic acid as an Excipient

AU - Bakhtiani, Parkash A.

AU - Caputo, Nicholas

AU - Castle, Jessica

AU - El Youssef, Joseph

AU - Carroll, Julie M.

AU - David, Larry

AU - Roberts, Charles

AU - Kenneth, Ward

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Commercial glucagon is unstable due to aggregation and degradation. In closed-loop studies, it must be reconstituted frequently. For use in a portable pump for 3 days, a more stable preparation is required. At alkaline pH, curcumin inhibited glucagon aggregation. However, curcumin is not sufficiently stable for long-Term use. Here, we evaluated ferulic acid, a stable breakdown product of curcumin, for its ability to stabilize glucagon. Methods: Ferulic acid-formulated glucagon (FAFG), composed of ferulic acid, glucagon, L-methionine, polysorbate-80, and human serum albumin in glycine buffer at pH 9, was aged for 7 days at 37°C. Glucagon aggregation was assessed by transmission electron microscopy (TEM) and degradation by high-performance liquid chromatography (HPLC). A cell-based protein kinase A (PKA) assay was used to assess in vitro bioactivity. Pharmacodynamics (PD) of unaged FAFG, 7-day aged FAFG, and unaged synthetic glucagon was determined in octreotide-Treated swine. Results: No fibrils were observed in TEM images of fresh or aged FAFG. Aged FAFG was 94% intact based on HPLC analysis and there was no loss of bioactivity. In the PD swine analysis, the rise over baseline of glucose with unaged FAFG, aged FAFG, and synthetic native glucagon (unmodified human sequence) was similar. Conclusions: After 7 days of aging at 37°C, an alkaline ferulic acid formulation of glucagon exhibited significantly less aggregation and degradation than that seen with native glucagon and was bioactive in vitro and in vivo. Thus, this formulation may be stable for 3-7 days in a portable pump for bihormonal closed-loop treatment of T1D.

AB - Background: Commercial glucagon is unstable due to aggregation and degradation. In closed-loop studies, it must be reconstituted frequently. For use in a portable pump for 3 days, a more stable preparation is required. At alkaline pH, curcumin inhibited glucagon aggregation. However, curcumin is not sufficiently stable for long-Term use. Here, we evaluated ferulic acid, a stable breakdown product of curcumin, for its ability to stabilize glucagon. Methods: Ferulic acid-formulated glucagon (FAFG), composed of ferulic acid, glucagon, L-methionine, polysorbate-80, and human serum albumin in glycine buffer at pH 9, was aged for 7 days at 37°C. Glucagon aggregation was assessed by transmission electron microscopy (TEM) and degradation by high-performance liquid chromatography (HPLC). A cell-based protein kinase A (PKA) assay was used to assess in vitro bioactivity. Pharmacodynamics (PD) of unaged FAFG, 7-day aged FAFG, and unaged synthetic glucagon was determined in octreotide-Treated swine. Results: No fibrils were observed in TEM images of fresh or aged FAFG. Aged FAFG was 94% intact based on HPLC analysis and there was no loss of bioactivity. In the PD swine analysis, the rise over baseline of glucose with unaged FAFG, aged FAFG, and synthetic native glucagon (unmodified human sequence) was similar. Conclusions: After 7 days of aging at 37°C, an alkaline ferulic acid formulation of glucagon exhibited significantly less aggregation and degradation than that seen with native glucagon and was bioactive in vitro and in vivo. Thus, this formulation may be stable for 3-7 days in a portable pump for bihormonal closed-loop treatment of T1D.

KW - closed-loop system

KW - ferulic acid

KW - glucagon

KW - hypoglycemia

KW - type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84942809679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942809679&partnerID=8YFLogxK

U2 - 10.1177/1932296814552476

DO - 10.1177/1932296814552476

M3 - Article

VL - 9

SP - 17

EP - 23

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 1

ER -